CMS Open Payments · Program Year 2024
Pharming Healthcare, Inc.
Pharming Healthcare, Inc. reported $1,902,006.34 across General Payments, Research, and Ownership to 6,200 physicians and teaching hospitals across 6,230 transactions.
- $1.9M
- All-tracks total
- 6,230
- Transactions
- 6,200
- Recipients
- +$256.3K
- General Payments vs PY2023
Pharming Healthcare, Inc. reported $1,902,006.34 across all CMS Open Payments tracks (General + Research + Ownership) to 6,200 physicians and teaching hospitals in Program Year 2024 - ranking #463 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,550,244.25, averaging $306.78 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer pharming-healthcare-inc Pharming Healthcare, Inc.
$1.9M · #463/1,925 · 0.0% industry · PY2024
- TOT $1.9M
- RANK #463
- SHARE 0.0%
- TXN 6,230
- RCP 6,200
- CAT 5
- GEN $1.6M
- ΔGEN +$256.3K
- TOP1 8.4%
- PY 2024
Volume peers
Nearest volume peer: Lantheus Medical Imaging, Inc. ($1.9M)
Pharming Healthcare, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Pharming Healthcare, Inc.'s CMS-reported General Payments increased by $256.3K (+19.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PHARMING HEALTHCARE, INC.PY2023: PHARMING HEALTHCARE, INC.PY2024: Pharming Healthcare, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,293,910.55
- PY2024
- $1,550,244.25
What the Data Shows for Pharming Healthcare, Inc.
Pharming Healthcare, Inc. ranks #463 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $1,902,006.34 across 6,230 transactions to 6,200 physicians and teaching hospitals - $305.30 per transaction and $306.78 per recipient on average.
Of the 5 general-payment categories charted below, "Consulting Fee" is the largest at $1.2M across 388 transactions, 78.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Pharming Healthcare, Inc.'s 5-category general-payment breakdown at $1.2M, 78.0% of the reported total.
Pharming Healthcare, Inc. reports 5 general-payment categories - the top three are Consulting Fee (78.0%), Food and Beverage (11.3%), and Travel and Lodging (9.7%). The remaining 2 categories make up 1.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Pharming Healthcare, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $1.2M | 388 | 78.0% |
| Food and Beverage | $174.8K | 5,040 | 11.3% |
| Travel and Lodging | $150.1K | 734 | 9.7% |
| Compensation for Services Other Than Consulting | $15.4K | 8 | 1.0% |
| Education | $780.00 | 30 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $369,226.23 (23.8%) of $1,550,244.25 in this company's General Payments records across 2,416 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Pharming Healthcare, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Raffi Tachdjian
$130,489.60 across 161 reported transactions
- 2
Jack Eades
$69,212.83 across 90 reported transactions
- 3
Nicholas Hartog
$65,032.58 across 59 reported transactions
- 4
Matthew Kreth
$53,393.45 across 63 reported transactions
- 5
Niraj Patel
$51,097.77 across 51 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Pharming Healthcare, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Pharming Healthcare, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Pharming Healthcare, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Milestone Scientific Inc.
iRhythm Technologies, Inc.
Spark Therapeutics, Inc.
Applied Medical Resources Corporation
Acrotech Biopharma Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.